A1AAC

Tucatinib

Created: 2023-12-12
Last modified:  2024-12-18

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count60
Chiral Atom Count0
Bond Count65
Aromatic Bond Count27
2D diagram of A1AAC
Toggle HydrogenToggle Labels

Chemical Component Summary

NameTucatinib
SynonymsN~6~-(4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl)-N~4~-(3-methyl-4-{[(4R)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]oxy}phenyl)quinazoline-4,6-diamine; Tukysa; ONT-380; ARRY-380
Systematic Name (OpenEye OEToolkits)~{N}6-(4,4-dimethyl-5~{H}-1,3-oxazol-2-yl)-~{N}4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine
FormulaC26 H24 N8 O2
Molecular Weight480.521
TypeNON-POLYMER

Chemical Descriptors

TypeProgram Version Descriptor
SMILESACDLabs12.01CC1(C)N=C(Nc2cc3c(Nc4cc(C)c(Oc5cc6ncnn6cc5)cc4)ncnc3cc2)OC1
SMILESCACTVS3.385Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc5ccn6ncnc6c5
SMILESOpenEye OEToolkits2.0.7Cc1cc(ccc1Oc2ccn3c(c2)ncn3)Nc4c5cc(ccc5ncn4)NC6=NC(CO6)(C)C
Canonical SMILESCACTVS3.385 Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc5ccn6ncnc6c5
Canonical SMILESOpenEye OEToolkits2.0.7 Cc1cc(ccc1Oc2ccn3c(c2)ncn3)Nc4c5cc(ccc5ncn4)NC6=NC(CO6)(C)C
InChIInChI1.06 InChI=1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31)
InChIKeyInChI1.06 SDEAXTCZPQIFQM-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank IDDB11652 
NameTucatinib
Groups
  • approved
  • investigational
DescriptionTucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.[L12951] Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.[L12945]
SynonymsTucatinib
Brand NamesTukysa
IndicationTucatinib is indicated with [trastuzumab] and [capecitabine] for the treatment of adults diagnosed with advanced unresectable or metastatic HER2-positive breast cancer. This includes patients with brain metastases and those who have received one or more prior anti-HER2-based regimens in the metastatic setting.[L12945] It is also indicated in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This indication is approved under accelerated approval; thus, it is contingent upon verification and description of clinical benefit in confirmatory trials.[L44732]
Categories
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • BCRP/ABCG2 Substrates
  • Cytochrome P-450 CYP2C8 Inhibitors
  • Cytochrome P-450 CYP2C8 Substrates
ATC-CodeL01EH03
CAS number937263-43-9

Drug Targets

NameTarget SequencePharmacological ActionActions
Receptor tyrosine-protein kinase erbB-2MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLY...unknowninhibitor
Receptor tyrosine-protein kinase erbB-3MRANDALQVLGLLFSLARGSEVGNSQAVCPGTLNGLSVTGDAENQYQTLY...unknowninhibitor
Cytochrome P450 2C8MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDI...unknownsubstrate
Cytochrome P450 3A SubfamilyMALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
Receptor tyrosine-protein kinase erbB-2MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLY...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682